New Onset of Giant Cell Arteritis following ChAdOx1-S (Vaxevria ® ) Vaccine Administration.
Luca Lo SardoSimone ParisiMaria Chiara DittoRosanna De GiovanniFrancesca MalettaSerena GrimaldiLuisa BrussinoEnrico FusaroPublished in: Vaccines (2023)
We report a 78-year-old man presenting with persistent headaches in vertex and temporo-parietal area; fatigue, worsening after walking; jaw claudication; scotomas; pharyngodynia; and dry cough after the second dose of the SARS-CoV-2 vaccine (ChAdOx1-S) administration. Laboratory findings showed an elevated C-reactive protein level and FDG-CT PET showed evidence of active large vessel vasculitis with diffuse abnormal artery uptake. Under suspicion of vasculitis, a temporal arteries biopsy was performed; the histopathologic findings demonstrated the transmural inflammatory infiltrate with giant cells, compatible with giant cell arteritis. Although the overall incidence of vaccine-triggered autoimmunity is low, rheumatologists worldwide should be aware of autoimmune diseases as a new potential adverse event of vaccines.
Keyphrases
- giant cell
- sars cov
- positron emission tomography
- computed tomography
- pet ct
- induced apoptosis
- pet imaging
- oxidative stress
- working memory
- cell cycle arrest
- respiratory syndrome coronavirus
- low grade
- contrast enhanced
- magnetic resonance
- depressive symptoms
- sleep quality
- signaling pathway
- case report
- climate change
- endoplasmic reticulum stress
- high grade
- celiac disease
- peripheral artery disease